Ozempic ® may cause serious side effects, including:
What is the most important information I should know about Ozempic ® ? You may give other people a serious infection, or get a serious infection from them.
Selected Important Safety Information for Ozempic ®ĭo not share your Ozempic ® pen with other people, even if the needle has been changed.
It is not known if Ozempic ® is safe and effective for use in children under 18 years of age. Ozempic ® is not a substitute for insulin and is not for use in people with type 1 diabetes or people with diabetic ketoacidosis. It is not known if Ozempic ® can be used in people who have had pancreatitis. Ozempic ® is not recommended as the first choice of medicine for treating diabetes. Ozempic ® (semaglutide) injection 0.5 mg or 1 mg is an injectable prescription medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Please visit for more information about Fiasp ®. More information on the Novo Nordisk Patient Assistance Program is available by calling 86. Fiasp ® is also available to eligible patients through the Novo Nordisk Patient Assistance Program. For more information about the instant savings card, please visit or call 87. 2 The list price of Fiasp ® is the same as mealtime insulin NovoLog ® and eligible patients with commercial insurance can use the Novo Nordisk Instant Savings Card to reduce co-pays for Fiasp ® to as low as $25 per 30-day supply for up to two years. Fiasp ® should be administered at the beginning of a meal or within 20 minutes after starting a meal due to its appearance in the blood in approximately 2.5 minutes. Please visit for more information about Ozempic ®.įiasp ® is the first fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Ozempic ® is priced at parity to current market-leading weekly GLP-1 receptor agonists, and eligible patients with commercial insurance can use the Ozempic ® Instant Savings Card to reduce co-pays to as low as $25 per prescription fill for up to two years. In clinical trials, Ozempic ® demonstrated statistically significant A1C reductions. Our robust portfolio of diabetes products addresses the concerns and needs of people with diabetes, particularly around dosing and administration." "There is no one-size-fits-all approach to effectively managing diabetes and we are proud to add Ozempic ® and Fiasp ® to our market-leading portfolio to give patients new treatment options. "With 1.5 million new patients diagnosed with diabetes each year, 3 we must continue to innovate and bring to market new options to meet the diverse needs of patients," said David Moore, senior vice president, Commercial, Novo Nordisk. Food and Drug Administration (FDA) in 2017 and represent the latest advancements to Novo Nordisk's robust diabetes portfolio. 2īoth medications received approval from the U.S. Fiasp ® is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Ozempic ® is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. 
5, 2018 /PRNewswire/ - Novo Nordisk today announced the availability of two new diabetes medications, Ozempic ® (semaglutide) injection 0.5 mg or 1 mg and Fiasp ® (insulin aspart injection) 100 Units/mL at pharmacies across the United States.
0 kommentar(er)
